Dr. Reddy's Laboratories Limited (BOM:500124)
India
· Delayed Price · Currency is INR | Market Cap | 1.10T |
| Revenue (ttm) | 325.54B |
| Net Income (ttm) | 56.54B |
| Shares Out | 832.12M |
| EPS (ttm) | 67.78 |
| PE Ratio | 19.56 |
| Forward PE | 19.51 |
| Dividend | 8.00 (0.60%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 31,988 |
| Average Volume | 80,060 |
| Open | 1,319.50 |
| Previous Close | 1,312.75 |
| Day's Range | 1,305.00 - 1,331.25 |
| 52-Week Range | 1,025.90 - 1,420.20 |
| Beta | 0.39 |
| RSI | 64.38 |
| Earnings Date | Jul 25, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI seg... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Nifty 50 top losers today, June 17: Adani Enterprises, Dr. Reddy’s, Tata Motors, Sun Pharma lead declines
Indian equity benchmarks closed lower on Tuesday, June 17, 2025, as cautious market sentiment weighed on investor confidence. The BSE Sensex dropped 212.85 points (0.26%) to settle at 81,583.30, while...
Pharma stocks in focus as Trump announces tariffs on sector ‘soon’
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenu...
Nifty 50 top losers today, June 16: Tata Motors, Dr. Reddy’s, Sun Pharma, Adani Ports and Jio Financial Services
Indian equity markets closed on a strong note on June 16, 2025, with broad-based gains across major sectors. The BSE Sensex surged 677.55 points (0.84%) to close at 81,796.15, while the NSE Nifty 50 g...
Stocks to watch on June 12: Tata Comm, Max Health, Dr Reddy’s, HDFC Life, PayTM in focus on brokerage views
Several brokerages have released their latest views and price targets on key listed companies. Here are the highlights of fund house recommendations for the day: CLSA on Tata Communications: Maintain ...
Nomura upbeat on Dr. Reddy’s long-term prospects; maintains ‘Buy’ call with Rs 1,575 target
Nomura has maintained its Buy rating on Dr. Reddy’s Laboratories, setting a target price of ₹1,575, following the company’s strategic roadmap shared during a recent management interaction. The company...
Nifty 50 top gainers this week (June 7): Eternal, Shriram Finance, Dr. Reddy’s, Mahindra & Mahindra and more
Indian stock markets closed the week on a positive note, rebounding after two straight weeks of losses. A surprise policy pivot by the Reserve Bank of India (RBI) boosted investor sentiment, especiall...
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech (NASDAQ: ALVO) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE: RDY) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for gl...
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).
Nifty 50 top gainers today, June 5: Eternal, Trent, Dr. Reddy’s, Power Grid, ICICI Bank and more
Indian equity markets continued their upward momentum on June 5, with the Nifty 50 closing above the 24,750 level. The Sensex gained 443.79 points, or 0.55%, to close at 81,442.04, while the Nifty 50 ...
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)
Dr. Reddy’s shares surge 4% after company partners with Alvotech to develop and commercialize Biosimilar to Keytruda
Shares of Dr. Reddy’s Laboratories rose 4% in morning trade after the company announced a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilars. The two companies wi...
Dr. Reddy’s and Alvotech partner to develop and commercialize Biosimilar to Keytruda
Dr. Reddy’s Laboratories Ltd., a leading Indian pharmaceutical company, has entered into a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilar medicines. The partne...
Stocks to watch on news today: Dr Reddy’s, Sun Pharma, BEL, JSW Steel, NBCC, Max Healthcare, PNC Infra in focus
Several companies are likely to remain in focus today owing to key regulatory updates, project wins, acquisitions, and strategic corporate announcements. Dr Reddy’s Laboratories received two observati...
Dr Reddy's receives two USFDA observations for New York API facility
Dr. Reddy's Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these ...
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
JP Morgan, Goldman Sachs & more: Top stocks on brokers' radar for today
Brokerage firms have varying outlooks on Indian companies. JP Morgan is underweight on Dr. Reddy's due to margin concerns, while Citigroup maintains a buy rating on Biocon despite weak numbers. Nomura...
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's
Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans ...
Generics won't be affected by Trump's pricing policy, says Dr. Reddy's
Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans ...
Dr. Reddy's (RDY) Surpasses Q4 2025 Earnings and Revenue Expectations
Dr. Reddy's (RDY) Surpasses Q4 2025 Earnings and Revenue Expectations
Dr. Reddy’s Laboratories shares surge 3% as Nomura reaffirms Buy’ rating, raising target price to Rs 1,575
Dr. Reddy’s Laboratories (DRL) saw its stock price jump by 3% after Nomura upgraded its outlook, reaffirming a ‘Buy’ rating and raising the target price to ₹1,575. This upgrade follows a robust Q4 per...
Dr. Reddy's GAAP EPS of $0.22 beats by $0.02, revenue of $996M beats by $13.8M
Stocks to watch on brokerages: Pidilite, Swiggy, Thermax among top shares to buy; mixed calls on Dr. Reddy’s, ABB [May 12]
Brokerage houses have issued fresh reports on several key companies, with positive outlooks on names like Pidilite Industries, Swiggy, Thermax, and Bharti Airtel, while opinions remained divided on Dr...
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Dr Reddy’s Q4 PAT up 22%
Hyderabad: Dr Reddy's Laboratories posted a consolidated 22% jump in profit after tax attributable to equity holders at Rs 1,594 crore for the fourth .